TABLE 4.

Favorable response rates for patients who received regimens that included extended-spectrum cephalosporins that were shown to be effective against the infecting organism by in vitro susceptibility testing for more than 5 days^a

Time of therapy	No. of patients with favorable response/ no. of patients evaluated (%)b			Pc
	ESBL group	Non-ESBL group	Total
3rd day	6/17 (35.3) [1]	33/51 (64.7) [0]	39/68 (57.4) [2]	0.035
5th day	6/17 (35.3) [4]	36/50 (72.0) [1]	42/67 (62.7) [5]	0.007
End	9/17 (52.9) [4]	47/50 (94.0) [1]	56/67 (83.6) [5]	<0.001

^aEffective aminoglycosides were also administered during the course of cephalosporin therapy for 64.7% of the patients in the ESBL group and 78.4% of the patients in the non-ESBL group (P = 0.302).

^bThe values in brackets represent the number of fatal cases. The times from the onset of sepsis to the time of cephalosporin therapy were 3.17 ± 2.80 and 2.53 ± 2.83 days (mean ± standard deviation) for the ESBL and non-ESBL groups, respectively (the mean for all patients in both groups was 2.69 ± 2.75 days). The P value for the comparison of the times for the two groups was 0.401 by the Student t test.

^cP value by the Mann-Whitney U test.